Search Results for: covid-19
Articles
Traws Pharma Doses First Patient With Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 October 14, 2025
Traws Pharma, Inc. recently announced the dosing of the first subject in a Phase 2 study to evaluate ratutrelvir, a ritonavir-free...Invivyd Announces US IND Clearance & Alignment With FDA on Pivotal Clinical Program for a Vaccine-Alternative Antibody to Prevent COVID October 6, 2025
Invivyd, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application and provided feedback to...Symbiosis Expands Sterile Manufacturing Capacity With Fill/Finish Line Qualification September 30, 2025
Symbiosis Pharmaceutical Services has successfully completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production...AIM ImmunoTech Secures Patent Through 2039 for Novel Cancer Therapy September 25, 2025
AIM ImmunoTech Inc. recently announced the Japan Patent Office has issued a patent covering the Company’s proprietary use of Ampligen...LIPID SOURCING & SELECTION - Navigating the Lipid Landscape: Overcoming the Challenges of Lipid Sourcing & Selection for LNPs September 5, 2025
Donald Kelemen, PhD, says one of the most significant challenges lies in selecting and sourcing the molecules at the heart of LNPs: lipids. The right choices can optimize stability, efficacy, and scalability, while the wrong ones can introduce roadblocks that are difficult (and costly) to overcome.
Thermo Fisher Scientific Launches Gibco Expi293 PRO Expression System to Accelerate Protein Research & Therapeutic Drug Development August 20, 2025
Thermo Fisher Scientific has introduced the Gibco Expi293 PRO Expression System, a next-generation HEK293 transient expression system designed to deliver...Invivyd Announces Continued Neutralizing Activity of PEMGARDA & VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG August 18, 2025
Invivyd, Inc. recently announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA (pemivibart) against the currently dominant and...Traws Pharma Receives Approval to Proceed With Phase 2 COVID Studies With Ratutrelvir August 18, 2025
Traws Pharma, Inc. recently announced receipt from the Human Research Ethics Committee (HREC) of approval to proceed with a Phase 2...Pioneering LNP Expert Dr. Pieter Cullis Joins Hongene’s Scientific Advisory Board August 5, 2025
Hongene, a global CDMO focused on nucleic acid raw materials and medicines, has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle…
Symbiosis Reaches Major Milestone With Injectable Drug Product July 31, 2025
Symbiosis Pharmaceutical Services recently announced the successful completion of its 1,000th sterile drug product batch, marking a significant milestone in...BioNTech Announces Strategic Transaction to Acquire CureVac June 13, 2025
BioNTech SE and CureVac N.V. recently announced they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to...Vaxart Reports Positive Clinical Data Demonstrating its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses Than its First-Generation Technology June 11, 2025
Vaxart, Inc. recently reported positive topline results from the Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine...SPECIAL FEATURE- Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure June 4, 2025
Contributor Cindy H. Dubin speaks with many CDMO professionals to get their insights and perspectives on the current state of the industry.
PROTEIN BARCODING - Streamlining mRNA Therapeutic & Vaccine Development June 3, 2025
Meredith Carpenter, PhD, reviews how lipid nanoparticles have emerged as a powerful tool for delivery due to their low immunogenicity compared to viral vectors, along with their ability to encapsulate and protect nucleic acids and facilitate their entry into cells.
EXECUTIVE INTERVIEW - Sanner Group: Building a Suite of World-Leading Services for its Customers June 2, 2025
Chris Gilmor, Vice President of Sales, Sanner of America, explains how Sanner’s Advance with Agility™ program helps its partners achieve faster development times and reduce time to market, and how the company embeds sustainable practices into its global business.
IMUNON Announces Oral Presentation Highlighting Unprecedented Survival Data From Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer May 23, 2025
IMUNON recently announced new positive data from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the...Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles May 12, 2025
Invivyd, Inc. recently announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs)...EXECUTIVE INTERVIEW - Botanical Solution Inc.: Launching a Revolution in Economical & Environmentally Sustainable QS-21 Vaccine Adjuvant Production May 7, 2025
Gastón Salinas, CEO of Botanical Solution Inc., discusses his company’s transition from agriculture to pharmaceuticals, addressing the global shortage of QS-21, and developing the QS-21 gold standard vaccine.
CELL-FREE GENE SYNTHESIS - Eliminating Critical Bottlenecks in Genetic Medicine Development April 3, 2025
Marc Unger explores the market trends, challenges, and opportunities new DNA production technologies provide to accelerate genetic advances in healthcare.
CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials April 3, 2025
Neil Vivian, MSc, says advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.
